Hoffmann-la Roche

This study tested a new targeted drug, pralsetinib, against standard chemotherapy in people with a specific type of advanced lung cancer (RET fusion-positive) who had not yet received treatment for their metastatic disease. The goal was to see if pralsetinib could better delay ca…

This early-phase study tested a new medicine called RO7565020 in healthy volunteers and people with chronic hepatitis B. The goal was to check safety, side effects, and how the drug moves through the body. The trial was stopped early, so results are limited.

This study tested a drug called basmisanil in children aged 2 to 14 with Dup15q syndrome, a rare genetic condition that affects development. The goal was to see if the drug could improve daily living skills like communication and movement. The trial was stopped early, and only 7 …

This study looked at adding atezolizumab to cabozantinib for people with advanced kidney cancer that got worse after immunotherapy. The goal was to see if the combination worked better than cabozantinib alone. The trial was stopped early, so results are limited. It involved 522 a…

This study looked at whether giving two immunotherapy drugs (tiragolumab and atezolizumab) before and after surgery, with or without chemotherapy, is safe and effective for people with early-stage non-small cell lung cancer. The trial enrolled 50 participants but was terminated e…

This study tested several drug combinations in 40 people with advanced stomach or gastroesophageal junction cancer that had not been treated before. The goal was to see which combinations worked best and were safe. The study was terminated early, so results are limited.